Form 6-K Vascular Biogenics Ltd. For: Aug 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus
August 15, 2016 12:20 PM EDTRoth Capital affirms VBL Therapeutics (Nasdaq: VBLT) at Buy with a price target of $17 following Q2 results reported earlier Monday.
Analyst Joseph Pantginis commented today, In June, VBLT updated clinical results from a Phase I/II trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer. The results showed a median overall... More
